Published date : 01 April 2015
Article date : 01 April 2015
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)
Source www.prnewswire.com
WhichMedicalDevice is a FREE resource created by clinicians for clinicians.
Registration is free and gives you unlimited access to all of the content and features of this website.
Find out more...Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...
Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.
We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.
